{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-001103","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.812486+00:00","generated_at":"2026-05-24T03:26:36.978123+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Silexion expands SIL204 development with dual-route plan; preclinical data support; H1 2026 human trials targeted","bullets":["Expanded development plan for SIL204 combines intratumoral and systemic administration for KRAS-driven pancreatic cancer.","Preclinical orthotopic model data show systemic SIL204 significantly inhibits tumor growth and reduces metastases.","Toxicology and pharmacodynamic studies planned through 2025; regulatory submissions to Israel Ministry of Health in H2 2025 and EU in H1 2026.","Goal to initiate SIL204 human trials in H1 2026 for advanced localized KRAS-driven pancreatic cancer.","First-generation product siG12DLoder previously showed overall survival benefit in Phase 2, supporting the expanded approach."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-001103","json":"https://secwatch.observer/filing/0001178913-25-001103.json","markdown":"https://secwatch.observer/filing/0001178913-25-001103.md","text":"https://secwatch.observer/filing/0001178913-25-001103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/0001178913-25-001103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325001103/zk2532912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:26:36.978123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}